Iambic CEO to Join Jefferies Healthcare Conference
Iambic's co-founder and CEO Tom Miller will attend the Jefferies Global Healthcare Conference in London, Nov. 16-19.
Updated on Nov. 9, 2026 in Biotech
Iambic, a Nasdaq-listed clinical-stage life sciences and technology company, announced that co-founder and CEO Tom Miller, PhD, will attend the Jefferies Global Healthcare Conference in London from November 16 to 19, 2026. Miller is also scheduled to join an AI drug discovery panel on November 18.
Why it matters
The appearance gives investors and industry observers a direct venue to hear from the leader of an AI-driven drug developer during a major European healthcare investment event. It reflects continued interest in companies that pair machine learning with automated chemistry and biology experimentation.
Iambic describes its IAM1363 drug candidate as advanced to clinic in approximately two years, a timeline the company frames against conventional development. The announcement itself does not report any panel findings or conference outcomes.
The players
Iambic
Iambic is a Nasdaq-listed clinical-stage life sciences and technology company that develops novel medicines using an AI-driven platform.
Tom Miller, PhD
Tom Miller is co-founder and chief executive of Iambic, leading the company's AI-driven drug discovery work.
Jefferies Global Healthcare Conference
The Jefferies Global Healthcare Conference is an annual investor event now in its 17th year, widely regarded as Europe's largest healthcare-focused conference.
The details
Iambic said Tom Miller, PhD, co-founder and CEO, will attend the Jefferies Global Healthcare Conference, held November 16 to 19 in London, and will join an AI drug discovery panel on November 18 at 2:00 PM GMT. The company's platform integrates proprietary AI with automated, scalable chemistry and biology experimentation, which it describes as molecular superintelligence. Its leading AI technologies include Enchant and NeuralPLexer.
Timeline
October 15, 2026: Iambic filed its final prospectus with the SEC under Rule 424(b).
November 16-19, 2026: Jefferies Global Healthcare Conference in London.
November 18, 2026, 2:00 PM GMT: Tom Miller joins AI drug discovery panel.
The Tech Race
Iambic's Enchant and NeuralPLexer systems are its core AI tools, and the company's IAM1363 candidate reaching the clinic in about two years is its main proof point. The conference appearance places those tools in front of investors as AI-first drug developers compete for clinical-stage credibility.
For readers tracking AI drug development, the panel offers a near-term opportunity to hear how an AI-first developer explains its platform's clinical progress. The announcement does not indicate any change to product availability or access.
The takeaway
AI-driven drug developers are increasingly measuring progress by how quickly candidates reach the clinic, and Iambic's roughly two-year timeline for IAM1363 is the benchmark its leadership will likely emphasize. Readers should watch for clinical data rather than conference remarks to judge that claim.
What happens next
Tom Miller is scheduled to join an AI drug discovery panel on November 18, 2026, at 2:00 PM GMT during the Jefferies Global Healthcare Conference in London.
Further reading
Explore more on Biotech developments in AI-driven drug discovery.
Source note: This article includes information reported by The Manila times.
